Antinuclear antibody seropositivity in patients with cutaneous T-cell lymphoma - 09/09/11
Abstract |
Background: We attempted to determine the frequency and clinical relevance of antinuclear antibody (ANA) testing and positive ANA test results in patients with cutaneous T-cell lymphoma (CTCL). Methods: A retrospective chart and computer record review was conducted to determine the frequency of ANA testing in CTCL patients and the rate of seropositivity. Patients with a positive ANA were further examined to define possible explanations of the positive test. Results: Of 381 patients with CTCL, 66 (17%) had ANA tests; 8 of these (12.1%) were found to have an ANA titer greater than or equal to 1:40. Of patients with a positive ANA test, one was found to have chronic cutaneous lupus erythematosus histologically and clinically mimicking CTCL. Others were found to have a comorbid connective tissue disorder, some had apparent drug-induced antinuclear antibodies, and some had no identifiable reason for a positive ANA test. Conclusion: ANA seropositivity does not appear to be increased in CTCL patients, and the ANA test remains a useful screening tool for differentiating between CTCL and connective tissue disorders. (J Am Acad Dermatol 1998;39:434-8.)
Le texte complet de cet article est disponible en PDF.Plan
Reprint requests: Madeleine Duvic, MD, Section of Dermatology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 28, Houston, TX 77030. |
|
0190-9622/98/$5.00 + 0 16/1/91716 |
Vol 39 - N° 3
P. 434-438 - septembre 1998 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?